MannKind Licenses Technosphere to Rose Pharma for Inhaled GLP-1 Weight-Loss Drug
MNKD sits 92% above its 52-week low of $2.23.
Summary
MannKind has entered a worldwide licensing and collaboration agreement with Rose Pharma to develop ROSE-010 Technosphere, an inhaled rapid-acting GLP-1 for weight management. MannKind will provide formulation and manufacturing support through Phase 1b, and in return receives an equity stake in Rose Pharma, board representation, and royalties on future sales. This expands MannKind's Technosphere platform into the high-value obesity market, leveraging its pulmonary delivery expertise. The deal adds a new pipeline asset with potential upside from royalties and equity, though financial terms were not disclosed. The program builds on prior feasibility work and four completed clinical trials for ROSE-010, including positive Phase 2a data in weight management and IBS. Next milestone is completion of Phase 1b, with Rose Pharma responsible for clinical development and commercialization.
At the time of this announcement, MNKD was trading at $4.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $2.23 to $6.51. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.